Evidence map›Paper›PMID 40862619›Full record

ArticleMicrobiology spectrum2025

Impact of obesity on the gut microbiome and inflammatory markers during SIV infection and antiretroviral therapy.

Casey M McGuire, Isaac R Cinco, Diana Takahashi, Kristin A Sauter, Melissa Kirigiti, Ilhem Messaoudi, Jonah B Sacha, Charles T Roberts, Paul Kievit

Abstract read
In one paragraph

Article in Microbiology spectrum, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Casey M McGuireDivision of Metabolic Health and Disease, Oregon National Primate Research Center (ONPRC), Beaverton, Oregon, USA.ORCID 0000-0002-8207-6599
Isaac R CincoDepartment of Microbiology, Immunology, and Molecular Genetics, University of Kentucky, Lexington, Kentucky, USA.
Diana TakahashiDivision of Metabolic Health and Disease, Oregon National Primate Research Center (ONPRC), Beaverton, Oregon, USA.
Kristin A SauterDivision of Metabolic Health and Disease, Oregon National Primate Research Center (ONPRC), Beaverton, Oregon, USA.ORCID 0000-0002-8721-3222
Melissa KirigitiDivision of Metabolic Health and Disease, Oregon National Primate Research Center (ONPRC), Beaverton, Oregon, USA.
Ilhem MessaoudiDepartment of Microbiology, Immunology, and Molecular Genetics, University of Kentucky, Lexington, Kentucky, USA.ORCID 0000-0003-3203-2405
Jonah B SachaDivision of Pathobiology and Immunology, ONPRC, Beaverton, Oregon, USA.ORCID 0000-0002-7633-3122
Charles T RobertsDivision of Metabolic Health and Disease, Oregon National Primate Research Center (ONPRC), Beaverton, Oregon, USA.ORCID 0000-0003-1756-5772
Paul KievitDivision of Metabolic Health and Disease, Oregon National Primate Research Center (ONPRC), Beaverton, Oregon, USA.ORCID 0000-0003-1989-2478

Funding

Upgrade of confocal microscopy at the Oregon National Primate Research CenterP51OD011092 · OD · OREGON HEALTH & SCIENCE UNIVERSITY · PI Bonnie J. Nagel · 2012 to 2026
$203.9M
University of Kentucky Markey Cancer Center Support Grant ECIA SupplementP30CA177558 · NCI · UNIVERSITY OF KENTUCKY · PI Jennifer F Rogers · 2013 to 2026
$38.3M
Post-acute metabolic sequelae of SARS-CoV-2 infection in nonhuman primatesR01DK122843 · NIDDK · OREGON HEALTH & SCIENCE UNIVERSITY · PI KIEVIT, PAUL, ROBERTS, CHARLES T · 2019 to 2023
$6.6M
The impact of gastric bypass on maternal and offspring metabolic healthR01DK123115 · NIDDK · OREGON HEALTH & SCIENCE UNIVERSITY · PI KIEVIT, PAUL · 2020 to 2023
$2.9M
High Performance Computing and Machine Learning Infrastructure for Oregon Life SciencesS10OD034224 · OD · OREGON HEALTH & SCIENCE UNIVERSITY · PI ELLROTT, KYLE · 2023 to 2023
$2.0M
NCI NIH HHS P30 CA177558NIDDK NIH HHS R01 DK122843NIDDK NIH HHS R01 DK123115NIH HHS P51 OD011092NIH HHS S10 OD034224
6 · The paper itself

Abstract

Dysbiosis and impaired gut barrier integrity contribute to chronic immune activation associated with both obesity and HIV infection. Given the increased incidence of obesity in people living with HIV, we explored the impact of obesity on the gut microbiome and microbial translocation (MT) biomarkers during HIV infection and antiretroviral therapy (ART). Lean and obese rhesus macaques were infected with simian immunodeficiency virus (SIV) and subsequently treated with ART. Obese animals exhibited higher initial MT and inflammation biomarkers that remained constant throughout the study, while lean animals exhibited significant increases in these biomarkers that approached levels observed in obese animals. Lean and obese animals exhibited similar observed amplicon sequence variants (ASVs) at baseline, with obese animals exhibiting reduced ASVs during acute SIV infection that rebounded after 39 weeks of ART treatment. Beta diversity differed between groups and was longitudinally altered in obese animals. Obese animals exhibited significant changes in differential abundance in four times as many bacterial genera compared to lean animals. Our finding that MT and inflammation biomarkers significantly changed in lean animals, while obese animals exhibited significant alterations in microbial diversity, suggests that microbiome changes and systemic inflammation may not directly correlate during SIV infection and ART.IMPORTANCEIn response to the obesity epidemic, the incidence of obesity at the time of HIV diagnosis has increased, but the impacts of pre-existing obesity throughout antiretroviral therapy (ART)-treated HIV infection remain underexplored. Both obesity and HIV infection have been associated with inflammatory and microbiome perturbations. Here, we utilized 16S rRNA amplicon sequencing and quantification of systemic inflammation markers to longitudinally characterize the fecal microbiome and systemic inflammation in lean and obese rhesus macaques throughout simian immunodeficiency virus (SIV) infection and ART. Lean animals exhibited marked increases in inflammatory markers corresponding with minimal gut microbiome perturbations throughout SIV infection and ART. In contrast, obese animals exhibited minimal inflammatory alterations corresponding with distinct differentially abundant fecal bacterial taxa throughout SIV infection and ART. Our results provide crucial insights into the interactions between pre-existing obesity, inflammation, and the gut microbiome that may aid in developing therapeutic strategies for obese individuals diagnosed with HIV.

Indexed as

Anti-Retroviral AgentsGastrointestinal MicrobiomeObesitySimian Acquired Immunodeficiency SyndromeAnimalsBacterial TranslocationBiomarkersDisease Models, AnimalDysbiosisHIV InfectionsInflammationMacaca mulattaMaleRNA, Ribosomal, 16SSimian Immunodeficiency VirusAnti-Retroviral AgentsBiomarkersRNA, Ribosomal, 16Santiretroviral therapygut microbiomehuman immunodeficiency virusinflammationobesitysimian immunodeficiency virus

Identifiers

PMID40862619
PMCPMC12502777

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.